Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Intensified Pre-Operative Epirubicin in Operable Breast Cancer
NCT00253500Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jun 2002
- Primary completion
- Sep 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin in breast cancer, sponsored by Case Comprehensive Cancer Center. Primary endpoint: Complete Pathological Response Rate at 4 weeks. Started Jun 2002; status: completed.
02
Drugs
epirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00253500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253500.